CN117751195A - 脓毒症内型和/或严重程度的诊断 - Google Patents

脓毒症内型和/或严重程度的诊断 Download PDF

Info

Publication number
CN117751195A
CN117751195A CN202280052217.XA CN202280052217A CN117751195A CN 117751195 A CN117751195 A CN 117751195A CN 202280052217 A CN202280052217 A CN 202280052217A CN 117751195 A CN117751195 A CN 117751195A
Authority
CN
China
Prior art keywords
endotype
signature
sepsis
lgals3bp
fech
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280052217.XA
Other languages
English (en)
Chinese (zh)
Inventor
罗伯特E·汉考克
A·巴格赫拉
G·科恩弗洛伊
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of British Columbia
Original Assignee
University of British Columbia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of British Columbia filed Critical University of British Columbia
Publication of CN117751195A publication Critical patent/CN117751195A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6809—Methods for determination or identification of nucleic acids involving differential detection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/686—Polymerase chain reaction [PCR]
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B30/00—Methods of screening libraries
    • C40B30/06—Methods of screening libraries by measuring effects on living organisms, tissues or cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G16B25/10—Gene or protein expression profiling; Expression-ratio estimation or normalisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/26—Infectious diseases, e.g. generalised sepsis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Pathology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Theoretical Computer Science (AREA)
  • General Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Evolutionary Biology (AREA)
  • Medical Informatics (AREA)
CN202280052217.XA 2021-05-25 2022-05-25 脓毒症内型和/或严重程度的诊断 Pending CN117751195A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163192746P 2021-05-25 2021-05-25
US63/192,746 2021-05-25
PCT/CA2022/050831 WO2022246553A1 (en) 2021-05-25 2022-05-25 Diagnostic for sepsis endotypes and/or severity

Publications (1)

Publication Number Publication Date
CN117751195A true CN117751195A (zh) 2024-03-22

Family

ID=84229117

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280052217.XA Pending CN117751195A (zh) 2021-05-25 2022-05-25 脓毒症内型和/或严重程度的诊断

Country Status (7)

Country Link
US (1) US20240254557A1 (enExample)
EP (1) EP4352250A4 (enExample)
JP (1) JP2024520049A (enExample)
CN (1) CN117751195A (enExample)
AU (1) AU2022283025A1 (enExample)
CA (1) CA3221576A1 (enExample)
WO (1) WO2022246553A1 (enExample)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118389664A (zh) * 2024-04-24 2024-07-26 南方医科大学深圳医院 区分正常患者和脓毒症患者的基因组合物、脓毒症和感染性休克的预测模型的构建方法
CN118621011A (zh) * 2024-06-18 2024-09-10 广东医科大学附属医院 circNfix作为生物标志物在检测、诊断或预后脓毒症急性肾损伤中的应用
CN120939040A (zh) * 2025-10-20 2025-11-14 四川省医学科学院·四川省人民医院 GYG1 siRNA在制备治疗脓毒症的药物中的应用
CN122283150A (zh) * 2026-05-29 2026-06-26 浙江省肿瘤医院 一种用于预测胰腺癌肝转移的胆汁蛋白标志物组合及其应用
CN122283150B (zh) * 2026-05-29 2026-08-21 浙江省肿瘤医院 一种用于预测胰腺癌肝转移的胆汁蛋白标志物组合及其应用

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024148050A2 (en) * 2023-01-04 2024-07-11 Ampel Biosolutions, Llc Longitudinal gene expression analysis of inflammatory skin diseases
EP4766855A1 (en) * 2023-08-22 2026-07-01 Ramot at Tel-Aviv University Ltd. SYSTEMIC RESISTANCE AND INFLAMMATION MARKERS AND THEIR USES
WO2025090733A1 (en) * 2023-10-27 2025-05-01 Sanofi Identifying disease subtypes

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050196817A1 (en) 2004-01-20 2005-09-08 Molecular Staging Inc. Biomarkers for sepsis
JP2008538007A (ja) 2005-04-15 2008-10-02 ベクトン,ディッキンソン アンド カンパニー 敗血症の診断
DE102005050933A1 (de) * 2005-10-21 2007-04-26 Justus-Liebig-Universität Giessen Erfindung betreffend Expressionsprofile zur Vorhersage von septischen Zuständen
US20110076685A1 (en) 2009-09-23 2011-03-31 Sirs-Lab Gmbh Method for in vitro detection and differentiation of pathophysiological conditions
US20110312521A1 (en) 2010-06-17 2011-12-22 Baylor Research Institute Genomic Transcriptional Analysis as a Tool for Identification of Pathogenic Diseases
EP2834638B1 (en) 2012-04-02 2020-02-12 Astute Medical, Inc. Methods for diagnosis and prognosis of sepsis
EP3013985A4 (en) 2013-06-28 2017-07-19 Acumen Research Laboratories Pte. Ltd. Sepsis biomarkers and uses thereof
WO2015117204A1 (en) * 2014-02-06 2015-08-13 Immunexpress Pty Ltd Biomarker signature method, and apparatus and kits therefor
CA2942577A1 (en) 2014-03-14 2015-09-17 Robert E. W. Hancock Diagnostic for sepsis
CN107532214B (zh) 2015-03-12 2021-08-31 斯坦福大学托管董事会 用于败血症诊断的方法
GB201518597D0 (en) * 2015-10-20 2015-12-02 Univ Liverpool Detection of bacterial infection
US11104953B2 (en) * 2016-05-13 2021-08-31 Children's Hospital Medical Center Septic shock endotyping strategy and mortality risk for clinical application
KR101929772B1 (ko) * 2016-11-02 2018-12-17 연세대학교 산학협력단 패혈증 진단을 위한 정보를 제공하는 방법 및 이를 이용한 키트
WO2018146162A1 (en) * 2017-02-07 2018-08-16 Academisch Medisch Centrum Molecular biomarker for prognosis of sepsis patients
US12571044B2 (en) * 2018-02-27 2026-03-10 The Board Of Trustees Of The Leland Stanford Junior University Classifier for identification of robust sepsis subtypes
US20210388443A1 (en) * 2018-11-05 2021-12-16 Institute For Systems Biology Sepsis biomarker panels and methods of use

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118389664A (zh) * 2024-04-24 2024-07-26 南方医科大学深圳医院 区分正常患者和脓毒症患者的基因组合物、脓毒症和感染性休克的预测模型的构建方法
CN118621011A (zh) * 2024-06-18 2024-09-10 广东医科大学附属医院 circNfix作为生物标志物在检测、诊断或预后脓毒症急性肾损伤中的应用
CN118621011B (zh) * 2024-06-18 2025-08-29 广东医科大学附属医院 circNfix作为生物标志物在检测、诊断或预后脓毒症急性肾损伤中的应用
CN120939040A (zh) * 2025-10-20 2025-11-14 四川省医学科学院·四川省人民医院 GYG1 siRNA在制备治疗脓毒症的药物中的应用
CN122283150A (zh) * 2026-05-29 2026-06-26 浙江省肿瘤医院 一种用于预测胰腺癌肝转移的胆汁蛋白标志物组合及其应用
CN122283150B (zh) * 2026-05-29 2026-08-21 浙江省肿瘤医院 一种用于预测胰腺癌肝转移的胆汁蛋白标志物组合及其应用

Also Published As

Publication number Publication date
AU2022283025A1 (en) 2024-01-18
EP4352250A4 (en) 2026-07-01
CA3221576A1 (en) 2022-12-01
US20240254557A1 (en) 2024-08-01
EP4352250A1 (en) 2024-04-17
WO2022246553A1 (en) 2022-12-01
JP2024520049A (ja) 2024-05-21

Similar Documents

Publication Publication Date Title
US12473597B2 (en) Methods and systems for processing a nucleic acid sample
AU2020201564B2 (en) Diagnostic for sepsis
US20240254557A1 (en) Diagnostic for sepsis endotypes and/or severity
KR102461014B1 (ko) 폐암 상태를 평가하는 방법
EP3103046B1 (en) Biomarker signature method, and apparatus and kits therefor
US11091809B2 (en) Molecular diagnostic test for cancer
US20240309469A1 (en) Methods to detect and treat a fungal infection
US20170088902A1 (en) Expression profiling for cancers treated with anti-angiogenic therapy
US20250084480A1 (en) Methods of treating eosinophilic colitis

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination